Akoya Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview

Akoya Biosciences

03/03/2023 21:22

* Akoya Biosciences Inc  AKYA.OQ   AKYA.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 6. 
    * The Marlborough Massachusetts-based  company is expected
to
report  a 27.4% increase in revenue to $20.583 million from
$16.16 million a year ago, according to the mean estimate from 5
analysts, based on Refinitiv data. The company's guidance on
January 8 2023, for the period ended December 31, was for
revenue between $20.70 million and $21.20 million.
    * ​Refinitiv's mean analyst estimate for Akoya Biosciences
Inc is
for a loss of 43 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akoya
Biosciences
Inc is $18​, above​ its last closing price of $11.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.49       -0.44      -0.47     Missed  -6.8
 Jun. 30 2022  -0.39       -0.37      -0.47     Missed  -26.3
 Mar. 31 2022  -0.40       -0.39      -0.44     Missed  -13.5​
 Dec. 31 2021  -0.29       -0.31      -0.47     Missed  -51.6
 ​​Sep.        -0.26       -0.26      -0.31     Missed  -17
 30 2021                                                
 Jun. 30 2021  -0.23       -0.23      -0.20     Beat    13​
 Mar. 31 2021  -0.17       -0.17      -3.54     Missed  -2,013
                                                        .4
 This summary was machine generated March 3 at 21:22 GMT.  All
figures in US dollars  unless otherwise stated